<DOC>
	<DOCNO>NCT01018173</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled parallel arm study ass efficacy safety effect taspoglutide cardiovascular event patient inadequately control type 2 diabetes mellitus establish cardiovascular disease . Patients randomize receive either taspoglutide subcutaneously ( sc ) 10mg weekly 4 week follow 20mg sc weekly , weekly sc placebo , addition background anti-hyperglycemic medication standard care treatment cardiovascular disease . Anticipated time study treatment 2 year . Target sample size 2000 patient .</brief_summary>
	<brief_title>A Study Taspoglutide Patients With Inadequately Controlled Diabetes Mellitus Type 2 Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>adult patient , &gt; 18 year age diabetes mellitus type 2 HbA1c &gt; /=6.5 % &lt; /=10 % screen BMI &gt; /=23kg/m2 cardiovascular disease onset &gt; /=1 month prior screen diagnosis history type 1 diabetes secondary form diabetes acute metabolic diabetic complication within past 6 month severe hypoglycemia &lt; /=1 month prior screen clinically significant gastrointestinal disease history chronic acute pancreatitis current New York Heart Association ( NYHA ) class IV heart failure posttransplantation cardiomyopathy severely impaired renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>